A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 401–500 of 1,138
Finding the cure for primary biliary cholangitis – Still waiting
Tanaka, A., & Gershwin, M. E. (2017) · Liver International · doi:10.1111/liv.13344 · Cited by 24
Deng, W., Fan, W., Tang, T., Wan, H., Zhao, S., Tan, Y., Agyare, O. K., Tan, J., Li, J., & Qu, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3589525 · Cited by 29
“Obeticholic acid (OCA) is the most promising synthetic FXR agonists that has been approved for the treatment of primary biliary cholangitis [18].”
Wilde, A. B., Lieb, C., Leicht, E., Greverath, L. M., Steinhagen, L. M., de Chamorro, N. W., Petersen, J., Hofmann, W. P., Hinrichsen, H. M., Heyne, R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051061 · Cited by 24
“67 × ULN and bilirubin normalization under obeticholic acid [27].”
BackgroundStructural basis of tropifexor as a potent and selective agonist of farnesoid X receptor
Jiang, L., Xiao, D., Li, Y., Dai, S., Qu, L., Chen, X., Guo, M., Wei, H., & Chen, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.039 · Cited by 26
ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis
Yao, Q., Wang, B., Yu, J., Pan, Q., Yu, Y., Feng, X., Chen, W., Yang, J., Gao, C., & Cao, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.006 · Cited by 24
Alvaro, D., Carpino, G., Craxì, A., Floreani, A., Moschetta, A., & Invernizzi, P. (2020) · Liver International · doi:10.1111/liv.14627 · Cited by 25
Self-citationZandanell, S., Straßer, M., Feldman, A., Tevini, J., Strebinger, G., Niederseer, D., Pohla‐Gubo, G., Huber-Schönauer, U., Ruhaltinger, S., Paulweber, B., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.13005 · Cited by 27
Steroidal or non-steroidal FXR agonists – Is that the question?
Verbeke, L., Nevens, F., & Laleman, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.013 · Cited by 25
Self-citationCheung, K. S., Seto, W., Fung, J., Lai, C., & Yuen, M. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2017.23 · Cited by 26
Cholestatic liver diseases: An era of emerging therapies
Samant, H. V., Manatsathit, W., Dies, D. F., Shokouh-Amiri, H. M., Zibari, G. B., Boktor, M., & Alexander, J. S. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i13.1571 · Cited by 26
Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value
Li, Z.-J., Gou, H.-Z., Zhang, Y., Song, X., & Zhang, L. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i44.6213 · Cited by 27
The Critical Role of Chemokine (C–C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis
Reuveni, D., Gore, Y., Leung, P. S. C., Lichter, Y., Moshkovits, I., Kaminitz, A., Brazowski, E., Lefebvre, E. A., Vig, P., Varol, C., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01852 · Cited by 25
“However, about 50% of patients with PBC still lack an adequate response to a combination of UDCA and obeticholic acid (37), and therefore, there is still a substantial medical need to develop new therapies for PBC.”
BackgroundWei, S., Ma, X., Niu, M., Wang, R., Yang, T., Wang, D., Wen, J., Li, H., & Zhao, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.586806 · Cited by 23
“However, there are some clinical problems with OCA, such as dyslipidaemia, which increases the risk of cardiovascular disease (Nevens et al., 2016), and pruritus in 50% of patients with PBC cannot be significantly improved (Hirschfield et al.”
BackgroundHernández‐Pérez, M., Riado, D., Pena, E., Méndez, C., Pinedo, F., Ramos, P., Castillo, P., Romero, M., Fernández‐Rodríguez, C., & Olveira, A. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18134 · Cited by 31
Pruritus in primary biliary cholangitis is under-recorded in patient medical records
Gungabissoon, U., Smith, H. T., von Maltzahn, R., Logie, J., Fairburn-Beech, J., Ma, L., Dhirishiya, P., McGirr, A. A., Hunnicutt, J. N., Rowe, C. L., et al. (2024) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2023-001287 · Cited by 26
Tanaka, A., Kono, H., Leung, P. S. C., & Gershwin, M. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.104021 · Cited by 24
Alkhouri, N., LaCerte, C., Edwards, J., Poordad, F., Lawitz, E., Lee, L., Karan, S., Sawhney, S., Erickson, M., MacConell, L., et al. (2024) · Liver International · doi:10.1111/liv.15816 · Cited by 23
Self-citationLachiondo‐Ortega, S., Mercado-Gómez, M., Serrano‐Maciá, M., Lopitz‐Otsoa, F., SALAS-VILLALOBOS, T. B., Varela‐Rey, M., Delgado, T. C., & Martínez‐Chantar, M. L. (2019) · Cells · doi:10.3390/cells8121575 · Cited by 23
“For those PBC patients with insufficient response or intolerance to UDCA, second-line therapy is obeticholic acid [30,31].”
BackgroundThe Role of Fibrates in Primary Biliary Cholangitis
Corpechot, C. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00455-3 · Cited by 25
Minuk, G. Y., Iliant, V., Zhou, N., Kaita, K., Wong, S. G., Peretz, D., & Uhanova, J. (2017) · Liver International · doi:10.1111/liv.13644 · Cited by 25
Jones, D. E. J., Wetten, A., Barron-Millar, B., Ogle, L., Mells, G., Flack, S., Sandford, R., Kirby, J., Palmer, J., Brotherston, S., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104068 · Cited by 22
Self-citationPPAR Agonists in Primary Biliary Cholangitis
Schnabl, B. (2024) · New England Journal of Medicine · doi:10.1056/nejme2313802 · Cited by 22
Klag, T., Thomas, M., Ehmann, D., Courth, L. F., Mailänder‐Sánchez, D., Weiß, T. S., Dayoub, R., Abshagen, K., Vollmar, B., Thasler, W. E., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01735 · Cited by 24
“Furthermore, the new FXR agonist obeticholic acid showed positive effects in PBC and is currently tested in PSC as well as non-alcoholic steatohepatitis (42, 44, 45).”
BackgroundZou, M., Wang, A., Wei, J., Cai, H., Yu, Z., Zhang, L., & Wang, X. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107328 · Cited by 24
Ueno, K., Aiba, Y., Hitomi, Y., Shimoda, S., Nakamura, H., Gervais, O., Kawai, Y., Kawashima, M., Nishida, N., Kohn, S.-S., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1497 · Cited by 22
“(1,2) Although the beneficial effects of obeticholic acid and bezafibrate have recently been reported in patients with ursodeoxycholic acid resistance, the long-term effects of obeticholic acid and bezafibrate have not been established.(3,4) Therefore, there is a substantial clinical need for new treatments based on a…”
BackgroundChen, W., Gao, X., Ma, L., Liu, Z.-B., Li, L., Wang, H., Gao, L., Xu, D., & Chen, Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7419249 · Cited by 21
Fuchs, C. D., SRODA, N., Scharnagl, H., Gupta, R. S., Minto, W. C., Stojaković, T., Liles, J. T., Budas, G. R., Hollenback, D., & Trauner, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100874 · Cited by 24
“pruritus and cholesterol changes) endemic to the class.(9,13,14) Indeed, data from a recent placebo-controlled study with the non-steroidal agonist, cilofexor, showed that administration at 30 mg or 100 mg q.”
BackgroundSelf-citationRojas, Á., García-Lozano, M. D. R., Gil‐Gómez, A., Romero‐Gómez, M., & Ampuero, J. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00247 · Cited by 22
Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology
Brønden, A., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz025 · Cited by 22
Beretta‐Piccoli, B. T., Guillod, C., Marsteller, I., Blum, R., Mazzucchelli, L., Mondino, C., Invernizzi, P., Gershwin, M. E., & Mainetti, C. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0448-0 · Cited by 20
“However, the available data are scant; there is a need for high-quality data on skin conditions associated with PBC. Keywords Primary biliary cholangitis · Acquired reactive perforating dermatosis · Skin disorders · Case report · Review of the literature”
BackgroundSelf-citationGerussi, A., D’Amato, D., Cristoferi, L., O’Donnell, S. E., Carbone, M., & Invernizzi, P. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.09.009 · Cited by 22
“[4] Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al.”
BackgroundInfluentialSelf-citationGungabissoon, U., Gibbons, D. C., Requena, G., Ribeiro de Souza, A., & Smith, H. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000857 · Cited by 20
Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease
van de Peppel, I. P., Bertolini, A., Jonker, J. W., Bodewes, F. A. J. A., & Verkade, H. J. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000428 · Cited by 22
Geoepidemiology and changing mortality in primary biliary cholangitis
Floreani, A., Tanaka, A., Bowlus, C. L., & Gershwin, M. E. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1333-2 · Cited by 21
Self-citationMicroenvironmental control of the ductular reaction: balancing repair and disease progression
Sorrentino, G. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07590-4 · Cited by 27
“In this context, genetic and pharmacological inhibition of Farnesoid X receptor (FXR), have also shown ef fi cacy in downregulating ductular proliferation and reducing hepatic fi brogenesis, re fl ecting broad anti fi brotic and anti-DR effects in cholestatic contexts [189, 190].”
Current and emerging adjuvant therapies in biliary atresia
Fligor, S. C., Hirsch, T. I., Tsikis, S. T., Adeola, A., & Puder, M. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1007813 · Cited by 25
“In a phase III trial for UDCA-resistant primary biliary cholangitis, obeticholic acid decreased alkaline phosphatase compared to placebo, although pruritis was a common side effect (62).”
BackgroundPresent and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
“…farnesoid X receptor (FXR) agonist, previously approved at a dosage of 5 and 10 mg as second-line treatment of primary biliary cholangitis [156,202] and now revoked from conditional marketing because its benefits were no longer considered to outweigh the risks of potential adverse events when…”
Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury
Iruzubieta, P., Goikoetxea‐Usandizaga, N., Barbier‐Torres, L., Serrano‐Maciá, M., Fernández‐Ramos, D., Fernández‐Tussy, P., Gutiérrez-de-Juan, V., Lachiondo‐Ortega, S., Simón, J., Bravo, M., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100276 · Cited by 27
“Both diseases can eventually progress to liver cirrhosis, liver failure, and death despite the currently available drug treatments.(2) Hepatic inflammation is an important feature of CLD in both humans and experimental animals.”
BackgroundLiver Capsule: FXR agonists against liver disease
Fuchs, C. D., Schwabl, P., Reiberger, T., & Trauner, M. (2016) · Hepatology · doi:10.1002/hep.28836 · Cited by 20
Self-citationLi, Y., Wang, K., Ding, J., Sun, S., Ni, Z., & Yu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.954684 · Cited by 23
“At present, OCA was one of the BA receptor modulators approved by the FDA for the clinical treatment of primary biliary cholangitis and effectively reversed or reduced the degree of liver damage in 2016 (Nevens et al., 2016).”
BackgroundYagi, M., Matsumoto, K., Komori, A., Abe, M., Hashimoto, N., Inao, M., Namisaki, T., Kawata, K., Ninomiya, M., Fujii, H., et al. (2020) · Liver International · doi:10.1111/liv.14534 · Cited by 20
Levy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003603 · Cited by 20
“UDCA does not improve pruritus, and obe-ticholic acid may actually worsen pruritus (5,7).”
Self-citationWang, J., Lou, C., Liu, G., Li, W., Wu, Z., & Tang, Y. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac351 · Cited by 23
Scott, J. A., Jones, A. M., Hanley, K. P., & Athwal, V. S. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16749 · Cited by 24
Aging-Related Molecular Pathways in Chronic Cholestatic Conditions
Pinto, C., Ninfole, E., Benedetti, A., Maroni, L., & Marzioni, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2019.00332 · Cited by 18
Zhou, D., Kong, L., Jiang, Y., Wang, C., Ni, Y., Wang, Y., Zhang, H., & Ruan, J. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108745 · Cited by 20
Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?
Molinaro, A., & Marschall, H. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0345-y · Cited by 19
Self-citationFXR/ASS1 axis attenuates the TAA-induced liver injury through arginine metabolism
Hong, W., Peng, X., Zhou, X., Li, P., Ye, Z., & Liang, W. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.073 · Cited by 21
Pathogenesis and Treatment of Pruritus Associated with Chronic Kidney Disease and Cholestasis
Kim, J. C., Shim, W., Kwak, I., Lee, D. H., Park, J. S., Lee, S., Kang, S. Y., Chung, B. Y., Park, C. W., & Kim, H. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021559 · Cited by 23
Marchianò, S., Biagioli, M., Roselli, R., Zampella, A., Giorgio, C. D., Bordoni, M., Bellini, R., Morretta, E., Monti, M. C., Distrutti, E., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202101397r · Cited by 21
Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)
Janmohamed, A., & Trivedi, P. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.002 · Cited by 21
Update on pharmacotherapies for cholestatic liver disease
Ali, A. H., Tabibian, J. H., & Lindor, K. D. (2016) · Hepatology Communications · doi:10.1002/hep4.1013 · Cited by 22
“Most recently, in a phase III clinical trial of OCA, 217 PBC patients (of whom 93% received UDCA at baseline and throughout the clinical trial) who demonstrated inadequate responses or intolerance to UDCA were randomly assigned to receive either OCA at a dose of 10mg/day (n5 73), 5mg/day for 6 months with an increase…”
MethodSelf-citationExploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis
Peeraphatdit, T. B., Simonetto, D. A., & Shah, V. H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.012 · Cited by 19
Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy
Stoelinga, A., Biewenga, M., Drenth, J. P. H., Verhelst, X., van der Meer, A. J. P., de Boer, Y. S., Bouma, G., de Vries, E. S., Verdonk, R. C., van den Berg, A. P., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101088 · Cited by 28
Self-citationUpdate on the Pharmacological Treatment of Primary Biliary Cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2022) · Biomedicines · doi:10.3390/biomedicines10082033 · Cited by 24
“The FDA approved OCA in 2016 after the results of the phase 3 international trial POISE, with a multicentric randomized controlled design, enrolling more than 200 PBC patients [24].”
BackgroundSelf-citationParés, A. R., Shiffman, M. L., Vargas, V., Invernizzi, P., Malecha, E. S., Liberman, A., MacConell, L., & Hirschfield, G. M. (2020) · Liver International · doi:10.1111/liv.14429 · Cited by 21
Self-citationRoda, A., Aldini, R., Camborata, C., Spinozzi, S., Franco, P., Cont, M., D’Errico, A., Vasuri, F., Degiovanni, A., Maroni, L., et al. (2017) · Clinical and Translational Science · doi:10.1111/cts.12468 · Cited by 19
Genetics of Primary Biliary Cholangitis
Gerussi, A., Asselta, R., & Invernizzi, P. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.002 · Cited by 18
Self-citationFrom pathogenesis to novel therapies in the treatment of primary biliary cholangitis
Ronca, V., Carbone, M., Bernuzzi, F., Malinverno, F., Mousa, H. S., Gershwin, M. E., & Invernizzi, P. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1391093 · Cited by 18
Self-citationNielsen, M. H., Nøhr-Meldgaard, J., Møllerhøj, M. B., Oró, D., Pors, S. E., Andersen, M. W., Kamzolas, I., Petsalaki, E., Vacca, M., Harder, L. M., et al. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2024 · Cited by 21
Emerging novel treatments for autoimmune liver diseases
Tanaka, A. (2019) · Hepatology Research · doi:10.1111/hepr.13347 · Cited by 19
Li, Y., Li, Z., Chen, R., Lian, M., Wang, H., Wei, Y., You, Z., Zhang, J., Li, B., Li, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37213-5 · Cited by 18
Brookhart, M. A., Mayne, T. J., Coombs, C., Breskin, A., Ness, E., Bessonova, L., Chu, Y. J., Li, J., Fried, M. W., Hansen, B. E., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001174 · Cited by 21
“[17] OCA-treated patients were censored if they initiated another PBC therapy (such as fibrates), out of similar concerns for confounding.”
InfluentialSelf-citationCançado, G. G. L., Braga, M. H., Ferraz, M. L. G., Villela‐Nogueira, C. A., Terrabuio, D. R. B., Cançado, E. L. R., Nardelli, M. J., Faria, L. C., Gomes, N. M. D. F., Oliveira, E. M. G., et al. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100546 · Cited by 20
Cançado, G. G. L., Braga, M. H., Ferraz, M. L. G., Villela‐Nogueira, C. A., Terrabuio, D. R. B., Cançado, E. L. R., Nardelli, M. J., Faria, L. C., Gomes, N. M. D. F., Oliveira, E. M. G., et al. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07122-y · Cited by 22
Progress in Primary Biliary Cholangitis
Carey, E. J. (2018) · New England Journal of Medicine · doi:10.1056/nejme1804945 · Cited by 24
Drug-Induced Liver Injury in the Setting of Chronic Liver Disease
Hoppmann, N. A., Gray, M. E., & McGuire, B. M. (2019) · Clinics in Liver Disease · doi:10.1016/j.cld.2019.09.006 · Cited by 17
Anti-Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct-Ligated Mice
Gee, L. M. V., Barron-Millar, B., Leslie, J., Richardson, C., Zaki, M. Y. W., Luli, S., Burgoyne, R. A., Cameron, R. I. T., Smith, G. R., Brain, J. G., et al. (2023) · The American Journal of Pathology · doi:10.1016/j.ajpath.2022.09.005 · Cited by 18
“In isolation, this observation could suggest either an indirect neuroprotective action of OCA through actively modulating bile acid synthesis and excretion 31 or a direct receptor-mediated action on neuronal cells.”
Self-citationPrognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis
Yamashita, Y., Umemura, T., Kimura, T., Joshita, S., Hirohara, J., Nakano, T., Komori, A., & Tanaka, A. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100662 · Cited by 22
New therapies target the toxic consequences of cholestatic liver disease
Jansen, P. L. M. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1424538 · Cited by 19
“As in PBC, pruritus and fatigue are leading symptoms.”
BackgroundMethodNovel targeted therapies for the management of liver fibrosis
Trivella, J. P., Martin, P. B., & Carrion, A. F. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1735350 · Cited by 21
“other markers such as HA, P3NP and TIMP-1) during follow up of up to 12 months [61,62].”
BackgroundLuo, X., & Lu, L. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00519 · Cited by 26
We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases
Lee, B. T., Tana, M. M.-S., Kahn, J. A., & Dara, L. (2021) · Hepatology · doi:10.1002/hep.31985 · Cited by 23
Wong, Y. J., Lam, L., Soret, P., Lemoinne, S., Hansen, B. E., Hirschfield, G. M., Gulamhusein, A. F., Lytvyak, E., Parés, A. R., Olivas, I., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.09.024 · Cited by 24
Self-citationThe role of non-apoptotic cell death in the treatment and drug-resistance of digestive tumors
Yang, Y., Bai, L., Liao, W., Feng, M., Zhang, M., Wu, Q., Zhou, K., Wen, F., Lei, W., Zhang, N., et al. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112678 · Cited by 19
Giannini, E. G., Pasta, A., Calabrese, F., Labanca, S., Marenco, S., Pieri, G., Torres, M. C. P., & Strazzabosco, M. (2024) · Liver International · doi:10.1111/liv.16222 · Cited by 21
“For these patients, obeticholic acid (OCA)—an FXR agonist—received conditional approval as second-line treatment, based on the results of a Phase III, 12-month, randomised, placebo-controlled trial that demonstrated its efficacy in improving biochemical endpoints [9].”
InfluentialBile acid‐activated receptors in innate and adaptive immunity: targeted drugs and biological agents
Cheung, K. C. P., Ma, J., Loiola, R. A., Chen, X., & Jia, W. P. (2023) · European Journal of Immunology · doi:10.1002/eji.202250299 · Cited by 24
Obeticholic Acid: A Farnesoid X Receptor Agonist for Primary Biliary Cholangitis
Smith, S. M., & Pegram, A. H. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122516687122 · Cited by 23
“OCA is a semisynthetic analog derived from the naturally occurring bile acid chenodeoxycholic acid, the primary human bile acid and a natural ligand for the farnesoid X receptor (FXR).11 FXRs are considered nuclear hormone receptors due to their action in the nucleus of hepatic and intestinal cells where they are pred…”
BackgroundInfluentialActivation of farnesoid X receptor signaling by geniposidic acid promotes osteogenesis
Liu, M., Jin, F., Zhang, S., Li, S., Zhu, D., Cui, Y., Cai, M., Liu, X., Zhang, Y., Sun, Y., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154258 · Cited by 19
Harms, M. H., Hirschfield, G. M., Floreani, A., Mayo, M. J., Parés, A., Liberman, A., Malecha, E. S., Pencek, R., MacConell, L., & Hansen, B. E. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2020.100191 · Cited by 17
Self-citationRoberts, S. B., Choi, W. J., Worobetz, L., Vincent, C., Flemming, J. A., Cheung, A., Qumosani, K. M., Swain, M. G., Grbic, D., Ko, H. H., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101168 · Cited by 33
“24 Limits of normal were based on site-speci fi c values.”
Self-citationHuang, D., Zhao, Y.-Y., Wang, R., Li, W., Yuan, F.-Y., Yan, X., Yang, X., Tang, G., Yin, S., & Bi, H. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00793-3 · Cited by 16
Mesenchymal Stem Cells as New Therapeutic Agents for the Treatment of Primary Biliary Cholangitis
Arsenijević, A., Harrell, C. R., Fellabaum, C., & Volarević, V. (2017) · Analytical Cellular Pathology · doi:10.1155/2017/7492836 · Cited by 25
Variant syndromes of primary biliary cholangitis
Schulz, L., Sebode, M., Weidemann, S. A., & Lohse, A. W. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.003 · Cited by 18
Wang, L., Sun, K., Ai, T. I. A. N., Yansheng, L. I. U., Zhang, M., Zhou, X., & Han, Y. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07316-x · Cited by 22
Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights
Zhu, C.-Y., Yu, P., Sun, Q., Hong, D., Yang, C., & Naranmandura, H. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107862 · Cited by 19
Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening
Diao, Y., Jiang, J., Zhang, S., Li, S., Shan, L., Huang, J. Y., Zhang, W., & Li, H. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00140 · Cited by 20
“, 2002), is the first FDA-approved drug that is used for treating primary biliary cholangitis (PBC) (Nevens et al., 2016).”
BackgroundLevy, C., Bowlus, C. L., Carey, E. J., Crawford, J. M., Deane, K., Mayo, M. J., Kim, W. R., & Fried, M. W. (2018) · Hepatology Communications · doi:10.1002/hep4.1173 · Cited by 16
Self-citationMontaño‐Loza, A. J., Lytvyak, E., Hirschfield, G. M., Hansen, B. E., Ebadi, M., Berney, T., Toso, C., Magini, G. M., Villamil, A., Nevens, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.010 · Cited by 17
Self-citationXu, C., Yue, R., Lv, X., Wang, S., & Du, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835991 · Cited by 17
“Three studies (Hirschfield et al., 2015; Nevens et al., 2016; Kowdley et al., 2018) compared the relief of pruritus after OCA treatment, and the heterogeneity among studies was low (p = 0.”
BackgroundGuo, F., Chen, K., Dong, H., Hu, D., Gao, Y., Liu, C., Laphookhieo, S., & Lei, X. (2022) · JACS Au · doi:10.1021/jacsau.2c00600 · Cited by 18
von Maltzahn, R., Mayo, M. J., Smith, H. T., Thompson, A. H., Das, S., de Souza, A. R., Lisi, E., Levy, C., McLaughlin, M., & Jones, D. E. (2024) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00722-y · Cited by 20
Self-citationThe pathophysiology of human obstructive cholestasis is mimicked in cholestatic Gold Syrian hamsters
van Golen, R. F., Olthof, P. B., de Haan, L. R., Coelen, R. J. S., Pechlivanis, A., de Keijzer, M. J., Weijer, R., de Waart, D. R., Kuilenburg, A. B. P., Roelofsen, J., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.11.022 · Cited by 16
Hof, W. F. J., de Boer, J. F., & Verkade, H. J. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2336986 · Cited by 21
“Nonetheless, inclusion in combination therapy with antipruritic agents remains a line of research [157,158].”
Goet, J. C., & Hirschfield, G. M. (2019) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101109 · Cited by 16
Self-citationLytvyak, E., Hirschfield, G. M., Shreekumar, D., Wong, Y. J., & Montaño‐Loza, A. J. (2025) · Liver International · doi:10.1111/liv.70190 · Cited by 20
“…double-blind, placebo-controlled, phase 3 RCT in PBC patients with inadequate response to UDCA, OCA showed greater biochemical improvement (ALP reduction) without any meaningful changes in non-invasive measures of liver fibrosis (LSM or ELF) at 12 months between treatment and placebo groups [154].”
Self-citationCurrent Therapeutics in Primary Sclerosing Cholangitis
Tan, N. P., Lubel, J. S., Kemp, W. W., Roberts, S. K., & Majeed, A. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00068s · Cited by 23
Ampuero, J., Lucena, A., Berenguer, M., Hernández-Guerra, M., Molina, E., Gómez-Camarero, J., Valdivia, C., Gómez, E., Casado, M., Álvarez-Navascuez, C., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000826 · Cited by 17
“Of note, POISE criteria were evaluated at 6 months of OCA treatment (rather than the twelve months indicated in the original clinical trial [6] ) to expedite the assessment of the risk of decompensation.”
Huang, D., Wang, R., Li, W., Zhao, Y.-Y., Yuan, F.-Y., Yan, X., Chen, Y., Tang, G., Bi, H., & Yin, S. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00277 · Cited by 16
Liver biopsy in primary biliary cholangitis: is sinusoidal fibrosis the missing key?
Warnes, T. W., Roberts, S. A., Smith, A., Haboubi, N. Y., & McMahon, R. F. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205958 · Cited by 18
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.